Delaware Superior Court — The Center of Zantac Litigation in 2026
Delaware Superior Court has emerged as the primary coordinated venue for Zantac state court litigation. Delaware is a natural forum for Zantac claims because major pharmaceutical defendants — including Sanofi and GSK — are incorporated in Delaware, supporting personal jurisdiction without complex minimum contacts analysis. Delaware uses the Frye evidentiary standard for expert testimony, which asks whether the scientific methodology is generally accepted in the relevant community rather than whether the specific expert's analysis is reliable under the Daubert gatekeeping inquiry. Delaware courts have issued coordinated case management orders covering thousands of consolidated Zantac cases, established bellwether trial schedules, and ruled on preliminary expert challenges. As of 2026, Delaware proceedings are advancing toward trial on selected bellwether cases that will help establish the settlement value of the broader pool of claims.
California State Courts — Active Dockets and Favorable Rulings
California state courts have been an active venue for Zantac litigation since 2021. California uses the Kelly/Frye general acceptance standard for novel scientific evidence, which differs from federal Daubert. California courts in Los Angeles, San Francisco, and Sacramento counties have heard and denied multiple defense motions for summary judgment based on causation arguments, allowing cases to proceed to trial. California's broad discovery rules and well-developed pharmaceutical tort litigation bar have supported efficient case development. California's 2-year statute of limitations with the discovery rule governs claims — claimants diagnosed with cancer from 2022 onward who can demonstrate delayed discovery of the Zantac connection, or who were diagnosed more recently, have viable filing windows in 2026.
How State Court Litigation Proceeds Differently From the MDL
In the federal MDL, a single Daubert ruling on general causation applied to all plaintiffs simultaneously — a winner-take-all structure that enabled defendants to eliminate the entire MDL with a single favorable expert exclusion ruling. State courts typically proceed differently. Coordinated proceedings in state courts often involve bellwether trials — individual cases tried to verdict that help establish the settlement value range for the broader pool. Even in coordinated proceedings, each case is ultimately adjudicated on its own facts. A ruling excluding one expert's methodology does not automatically eliminate every other plaintiff's case, because different plaintiffs may have different expert witnesses, different cancer types with varying evidentiary support, and different state-specific admissibility standards.
Other Active State Court Venues in 2026
Beyond Delaware and California, individual Zantac cases have been filed in state courts in Texas, Florida, New Jersey, Pennsylvania, Illinois, New York, and other states with significant plaintiff populations. These individual state filings are not coordinated in the same way as Delaware and California, but they proceed under each state's own rules and evidentiary standards. For claimants in states outside Delaware and California, a pharmaceutical litigation attorney can evaluate whether filing in their home state court, or transferring to a Delaware or California coordinated proceeding, is the optimal strategic approach based on that claimant's specific circumstances.
Frequently Asked Questions
Related Pages
Zantac NDMA Contamination Explained
NDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.
The Valisure Study — How the NDMA Problem Was Discovered
Valisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.
Zantac Settlement Expectations — State Court Litigation 2026
Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.
Zantac Statute of Limitations — State-by-State 2026 Analysis
The statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.
Cancers Covered by Zantac Litigation
Six cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.
Zantac and Bladder Cancer
Bladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.
Zantac Federal MDL Dismissal — What Happened
The federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.
Zantac Eligibility Requirements
To qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.
Zantac Brand vs. Generic — All Manufacturers Are Liable
The NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.
FDA Zantac Market Withdrawal — April 2020
On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.
Proving Zantac Use — How to Obtain Pharmacy Records
Pharmacy records are the single strongest form of evidence of long-term Zantac use for litigation purposes. Major pharmacy chains maintain prescription records and often OTC purchase histories for many years. Your attorney can assist in obtaining these records through HIPAA authorizations and subpoenas.
Zantac / Ranitidine (NDMA Cancer) Lawsuit
Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
View full case overview